Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial

被引：0
|
作者：
Wang, J. [1 ]
Wu, T. [1 ]
Hong, Y-G. [1 ]
Luo, S-X. [2 ]
Li, N. [2 ]
Guo, Y-Z. [3 ]
Cheng, Y-F. [4 ]
机构：
[1] Anyang Tumour Hosp, Med Oncol Dept, Anyang, Peoples R China
[2] Henan Canc Hosp, Med Oncol Dept, Zhengzhou, Peoples R China
[3] Henan Univ Sci & Technol, Affiliated Hosp 1, Med Oncol Dept, Luoyang, Peoples R China
[4] Shandong Univ, Qilu Hosp, Med Oncol Dept, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1513
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1404P
引用
收藏
页码：S1058 / S1058
页数：1
相关论文
共 50 条
  • [31] Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
    Wirth, Lori J.
    Brose, Marcia S.
    Sherman, Eric J.
    Licitra, Lisa
    Schlumberger, Martin
    Sherman, Steven, I
    Bible, Keith C.
    Robinson, Bruce
    Rodien, Patrice
    Godbert, Yann
    De La Fouchardiere, Christelle
    Newbold, Kate
    Nutting, Christopher
    Misir, Soamnauth
    Xie, Ran
    Almonte, Ana
    Ye, Weifei
    Cabanillas, Maria E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) : 2359 - +
  • [32] First-Line Treatment of Locally Advanced or Metastatic Pulmonary Lymphoepitheliomalikecarcinoma: A Multicenter, Single-Arm, Phase II Trial
    Zhou, C.
    Lin, X.
    Li, S.
    Sun, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S96 - S97
  • [33] Efficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A single-arm clinical trial
    Xiao, Zhehao
    Chen, Weiling
    Du, Youqin
    Zeng, Fanyan
    Su, Fang
    Huang, Shiting
    Qu, Song
    INTERNATIONAL JOURNAL OF CANCER, 2025,
  • [34] A phase II, open-label, single-arm study of QL1604 plus paclitaxel-cisplatin/carboplatin as first-line treatment in patients with recurrent or metastatic cervical cancer
    Liu, J.
    Fang, C.
    Zhou, Q.
    He, L.
    Yu, J.
    Li, Y.
    Feng, M.
    Pan, M.
    Zhao, L.
    Tang, D.
    Li, X.
    Tan, B.
    An, R.
    Zheng, X.
    Si, M.
    Zhang, B.
    Li, L.
    Kang, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S1506 - S1506
  • [35] A Single-Arm Phase II Study of Anlotinib Combined with Pemetrexed plus Cisplatin as a First-Line Therapy in Advanced NSCLC
    Xiong, J.
    Li, J.
    Deng, J.
    Zhang, W.
    Wang, H.
    Zeng, L.
    Shi, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S675 - S676
  • [36] Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial
    Negrier, Sylvie
    Rioux-Leclercq, Nathalie
    Ferlay, Celine
    Gross-Goupil, Marine
    Gravis, Gwenaelle
    Geoffrois, Lionel
    Chevreau, Christine
    Boyle, Helen
    Rolland, Frederic
    Blanc, Ellen
    Ravaud, Alain
    Dermeche, Slimane
    Flechon, Aude
    Albiges, Laurence
    Perol, David
    Escudier, Bernard
    EUROPEAN JOURNAL OF CANCER, 2020, 129 : 107 - 116
  • [37] Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment (NAT) for esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, phase. clinical trial.
    Zhang, Yan-Feng
    Li, Xiao-Bing
    Hong, Yong-Gui
    Li, Xiao-Ming
    Liang, Wei-Min
    Zheng, Zhi-Xin
    Yang, Guang-Yi
    Wen, Yan-Yan
    Cao, Heng
    Wu, Wei-Long
    Su, Wen-Zhong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 366 - 366
  • [38] Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II clinical trial
    Qiu, Tianzhu
    Mingjie, Lu
    Dong, Yuwen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 445 - 445
  • [39] Anlotinib in patients with recurrent advanced cervical cancer: A prospective single-arm, open-label, phase. trial.
    Wu, Xiaohua
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer: A multicenter, single-arm, phase I/II trial
    Pressiani, T.
    Balsano, R.
    Giordano, L.
    Milella, M.
    Bergamo, F.
    Bozzarelli, S.
    Noventa, S.
    Ferrari, D.
    Scartozzi, M.
    Parra, H. J. Soto
    Auriemma, A.
    Solda, C.
    Zaniboni, A.
    Zecchetto, C.
    Rizzato, M. D.
    Rimassa, L.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S120 - S120
12345